Overview

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Status:
Completed

Trial end date:
2016-11-24

Target enrollment:

Participant gender:

Summary

A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Interferon beta-1a
Interferon-beta
Interferons